A von Drygalski1, T J Cramer, V Bhat, J H Griffin, A J Gale, L O Mosnier. 1. Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA; Division of Hematology/Oncology, Department of Medicine, University California San Diego, San Diego, CA, USA.
Abstract
BACKGROUND: Factor (F)VIIa-based bypassing not always provides sufficient hemostasis in hemophilia. OBJECTIVES: To investigate the potential of engineered activated factor V (FVa) variants as bypassing agents in hemophilia A. METHODS: Activity of FVa variants was studied in vitro using prothrombinase assays with purified components and in FV- and FVIII-deficient plasma using clotting and thrombin generation assays. In vivo bleed reduction after the tail clip was studied in hemophilia A mice. RESULTS AND CONCLUSIONS: FVa mutations included a disulfide bond connecting the A2 and A3 domains and ones that rendered FVa resistant to inactivation by activated protein C (APC). '(super) FVa,' a combination of the A2-A3 disulfide (A2-SS-A3) to stabilize FVa and of APC-cleavage site mutations (Arg506/306/679Gln), had enhanced specific activity and complete APC resistance compared with wild-type FVa, FVL eiden (Arg506Gln), or FVaL eiden (A2-SS-A3). Furthermore, (super) FVa potently increased thrombin generation in vitro in FVIII-deficient plasma. In vivo, (super) FVa reduced bleeding in FVIII-deficient mice more effectively than wild-type FVa. Low-dose (super) FVa, but not wild-type FVa, decreased early blood loss during the first 10 min by more than two-fold compared with saline and provided bleed protection for the majority of mice, similar to treatments with FVIII. During the second 10 min after tail cut, (super) FVa at high dose, but not wild-type FVa, effectively reduced bleeding. These findings suggest that (super) FVa enhances not only clot formation but also clot stabilization. Thus, (super) FVa efficiently improved hemostasis in hemophilia in vitro and in vivo and may have potential therapeutic benefits as a novel bypassing agent in hemophilia.
BACKGROUND: Factor (F)VIIa-based bypassing not always provides sufficient hemostasis in hemophilia. OBJECTIVES: To investigate the potential of engineered activated factor V (FVa) variants as bypassing agents in hemophilia A. METHODS: Activity of FVa variants was studied in vitro using prothrombinase assays with purified components and in FV- and FVIII-deficient plasma using clotting and thrombin generation assays. In vivo bleed reduction after the tail clip was studied in hemophilia Amice. RESULTS AND CONCLUSIONS:FVa mutations included a disulfide bond connecting the A2 and A3 domains and ones that rendered FVa resistant to inactivation by activated protein C (APC). '(super) FVa,' a combination of the A2-A3 disulfide (A2-SS-A3) to stabilize FVa and of APC-cleavage site mutations (Arg506/306/679Gln), had enhanced specific activity and complete APC resistance compared with wild-type FVa, FVL eiden (Arg506Gln), or FVaL eiden (A2-SS-A3). Furthermore, (super) FVa potently increased thrombin generation in vitro in FVIII-deficient plasma. In vivo, (super) FVa reduced bleeding in FVIII-deficient mice more effectively than wild-type FVa. Low-dose (super) FVa, but not wild-type FVa, decreased early blood loss during the first 10 min by more than two-fold compared with saline and provided bleed protection for the majority of mice, similar to treatments with FVIII. During the second 10 min after tail cut, (super) FVa at high dose, but not wild-type FVa, effectively reduced bleeding. These findings suggest that (super) FVa enhances not only clot formation but also clot stabilization. Thus, (super) FVa efficiently improved hemostasis in hemophilia in vitro and in vivo and may have potential therapeutic benefits as a novel bypassing agent in hemophilia.
Authors: Erich V de Paula; Kaan Kavakli; Johnny Mahlangu; Yasmin Ayob; Steven R Lentz; Massimo Morfini; László Nemes; Silva Z Šalek; Midori Shima; Jerzy Windyga; Silke Ehrenforth; Ampaiwan Chuansumrit Journal: J Thromb Haemost Date: 2012-01 Impact factor: 5.824
Authors: Lacramioara Ivanciu; Raffaella Toso; Paris Margaritis; Giulia Pavani; Haein Kim; Alexander Schlachterman; Jian-Hua Liu; Valerie Clerin; Debra D Pittman; Rosalind Rose-Miranda; Kathleen M Shields; David V Erbe; James F Tobin; Valder R Arruda; Rodney M Camire Journal: Nat Biotechnol Date: 2011-10-23 Impact factor: 54.908
Authors: Bernhard C Lechtenberg; Thomas A Murray-Rust; Daniel J D Johnson; Ty E Adams; Sriram Krishnaswamy; Rodney M Camire; James A Huntington Journal: Blood Date: 2013-07-18 Impact factor: 22.113
Authors: Vikas Bhat; Annette von Drygalski; Andrew J Gale; John H Griffin; Laurent O Mosnier Journal: Thromb Haemost Date: 2015-10-15 Impact factor: 5.249
Authors: Annette von Drygalski; Vikas Bhat; Andrew J Gale; Patricia M Averell; Thomas J Cramer; Darlene J Elias; John H Griffin; Laurent O Mosnier Journal: Blood Adv Date: 2020-08-11
Authors: Andrew J Gale; Vikas Bhat; Jean-Luc Pellequer; John H Griffin; Laurent O Mosnier; Annette Von Drygalski Journal: Pharm Res Date: 2016-03-09 Impact factor: 4.200
Authors: Miguel Alejandro Lopez-Ramirez; Angela Pham; Romuald Girard; Tine Wyseure; Preston Hale; Atsuki Yamashita; Janne Koskimäki; Sean Polster; Laleh Saadat; Ignacio A Romero; Charles T Esmon; Frederic Lagarrigue; Issam A Awad; Laurent O Mosnier; Mark H Ginsberg Journal: Blood Date: 2018-11-15 Impact factor: 22.113
Authors: Daniel A Snellings; Courtney C Hong; Aileen A Ren; Miguel A Lopez-Ramirez; Romuald Girard; Abhinav Srinath; Douglas A Marchuk; Mark H Ginsberg; Issam A Awad; Mark L Kahn Journal: Circ Res Date: 2021-06-24 Impact factor: 23.213